{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:42:28Z","timestamp":1760820148550},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,3,28]],"date-time":"2009-03-28T00:00:00Z","timestamp":1238198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-244x-9-12","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T17:21:36Z","timestamp":1238433696000},"source":"Crossref","is-referenced-by-count":19,"title":["Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis"],"prefix":"10.1186","volume":"9","author":[{"given":"Virginia L","family":"Stauffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Lipkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki Poole","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra N","family":"Heinloth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Scott","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J","family":"Kinon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,28]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0269881107075509","volume":"21","author":"AH Barnett","year":"2007","unstructured":"Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones PB: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007, 21: 357-373. 10.1177\/0269881107075509.","journal-title":"J Psychopharmacol"},{"key":"560_CR2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999, 156: 1686-1696.","journal-title":"Am J Psychiatry"},{"key":"560_CR3","volume-title":"Zyprexa (Olanzapine) [package insert]","author":"Eli Lilly and Company","year":"2007","unstructured":"Eli Lilly and Company: Zyprexa (Olanzapine) [package insert]. 2007, Eli Lilly and Company, Indianapolis, IN"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1053\/j.gastro.2007.03.052","volume":"132","author":"CL Ogden","year":"2007","unstructured":"Ogden CL, Yanovski SZ, Carroll MD, Flegal KM: The epidemiology of obesity. Gastroenterology. 2007, 132: 2087-2102. 10.1053\/j.gastro.2007.03.052.","journal-title":"Gastroenterology"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.4088\/JCP.1106e16","volume":"67","author":"JW Newcomer","year":"2006","unstructured":"Newcomer JW: Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006, 67: e16-","journal-title":"J Clin Psychiatry"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"560_CR7","first-page":"258S","volume":"61","author":"W Deberdt","year":"2007","unstructured":"Deberdt W, Lipkovich I, Poole Hoffman V, Stauffer VL, Edwards SE, Hardy T, Kollack-Walker S: The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients with Schizophrenia or Schizoaffective Disorder [abstract]. Biol Psychiatry. 2007, 61: 258S-","journal-title":"Biol Psychiatry"},{"key":"560_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4088\/JCP.0607e14","volume":"68","author":"R Ganguli","year":"2007","unstructured":"Ganguli R: Behavioral Therapy for Weight Loss in Patients with Schizophrenia. J Clin Psychiatry. 2007, 68: 19-25.","journal-title":"J Clin Psychiatry"},{"key":"560_CR9","first-page":"CD005148","volume-title":"Cochrane Database Syst Rev","author":"G Faulkner","year":"2007","unstructured":"Faulkner G, Cohn T, Remington G: Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007, CD005148-"},{"key":"560_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","volume":"22","author":"T Baptista","year":"2008","unstructured":"Baptista T, Elfakih Y, Uzcategui E, Sandia I, Talamo E, raujo de BE, Beaulieu S: Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs. 2008, 22: 477-495. 10.2165\/00023210-200822060-00003.","journal-title":"CNS Drugs"},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/S1516-44462006000400005","volume":"28","author":"SS Assuncao","year":"2006","unstructured":"Assuncao SS, Ruschel SI, Rosa LC, Campos JA, Alves MJ, Bracco OL, de Lima MS: Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr. 2006, 28: 270-276.","journal-title":"Rev Bras Psiquiatr"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1440-1819.2003.01211.x","volume":"58","author":"WM Bahk","year":"2004","unstructured":"Bahk WM, Lee KU, Chae JH, Pae CU, Jun T, Kim KS: Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci. 2004, 58: 163-167. 10.1111\/j.1440-1819.2003.01211.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","volume":"15","author":"W Deberdt","year":"2005","unstructured":"Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A: Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005, 15: 13-21. 10.1016\/j.euroneuro.2004.03.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0924-977X(02)00127-X","volume":"13","author":"P Cavazzoni","year":"2003","unstructured":"Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB: Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003, 13: 81-85. 10.1016\/S0924-977X(02)00127-X.","journal-title":"Eur Neuropsychopharmacol"},{"key":"560_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-3999(85)90010-8","volume":"29","author":"AJ Stunkard","year":"1985","unstructured":"Stunkard AJ, Messick S: The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985, 29: 71-83. 10.1016\/0022-3999(85)90010-8.","journal-title":"J Psychosom Res"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1745-0179-2-29","volume":"2","author":"Y Khazaal","year":"2006","unstructured":"Khazaal Y, Fresard E, Zimmermann G, Trombert NM, Pomini V, Grasset F, Borgeat F, Zullino D: Eating and weight related cognitions in people with Schizophrenia: a case control study. Clin Pract Epidemol Ment Health. 2006, 2: 29-10.1186\/1745-0179-2-29.","journal-title":"Clin Pract Epidemol Ment Health"},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.schres.2006.12.025","volume":"91","author":"Y Khazaal","year":"2007","unstructured":"Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, Grasset F, Borgeat F, Zullino D: Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007, 91: 169-177. 10.1016\/j.schres.2006.12.025.","journal-title":"Schizophr Res"},{"key":"560_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/01.jcp.0000219916.88810.1c","volume":"26","author":"I Lipkovich","year":"2006","unstructured":"Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, Hardy T: Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006, 26: 316-320. 10.1097\/01.jcp.0000219916.88810.1c.","journal-title":"J Clin Psychopharmacol"},{"key":"560_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-244X-8-78","volume":"8","author":"I Lipkovich","year":"2008","unstructured":"Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry. 2008, 8: 78-10.1186\/1471-244X-8-78.","journal-title":"BMC Psychiatry"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4088\/JCP.v62n0404","volume":"62","author":"BR Basson","year":"2001","unstructured":"Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001, 62: 231-238.","journal-title":"J Clin Psychiatry"},{"key":"560_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/jcp.0b013e3181602fe6","volume":"28","author":"S Saddichha","year":"2008","unstructured":"Saddichha S, Ameen S, Akhtar S: Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008, 28: 27-31. 10.1097\/jcp.0b013e3181602fe6.","journal-title":"J Clin Psychopharmacol"},{"key":"560_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","volume":"25","author":"BJ Kinon","year":"2005","unstructured":"Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S: Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005, 25: 255-258. 10.1097\/01.jcp.0000161501.65890.22.","journal-title":"J Clin Psychopharmacol"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/hup.514","volume":"18","author":"M Atmaca","year":"2003","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol. 2003, 18: 457-461. 10.1002\/hup.514.","journal-title":"Hum Psychopharmacol"},{"key":"560_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1345\/aph.1D423","volume":"39","author":"EK Hester","year":"2005","unstructured":"Hester EK, Thrower MR: Current options in the management of olanzapine-associated weight gain. Ann Pharmacother. 2005, 39: 302-310. 10.1345\/aph.1D423.","journal-title":"Ann Pharmacother"},{"key":"560_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF02850000","volume":"24","author":"W Milano","year":"2007","unstructured":"Milano W, Grillo F, Del MA, De RM, Sanseverino B, Petrella C, Capasso A: Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther. 2007, 24: 123-134. 10.1007\/BF02850000.","journal-title":"Adv Ther"},{"key":"560_CR26","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1176\/appi.ajp.162.9.1744","volume":"162","author":"KA Graham","year":"2005","unstructured":"Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO: Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005, 162: 1744-1746. 10.1176\/appi.ajp.162.9.1744.","journal-title":"Am J Psychiatry"},{"key":"560_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.schres.2005.10.001","volume":"82","author":"JH Kim","year":"2006","unstructured":"Kim JH, Yim SJ, Nam JH: A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res. 2006, 82: 115-117. 10.1016\/j.schres.2005.10.001.","journal-title":"Schizophr Res"},{"key":"560_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/appi.ajp.160.2.297","volume":"160","author":"M Poyurovsky","year":"2003","unstructured":"Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A: Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry. 2003, 160: 297-302. 10.1176\/appi.ajp.160.2.297.","journal-title":"Am J Psychiatry"},{"key":"560_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","volume":"192","author":"M Poyurovsky","year":"2007","unstructured":"Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I: Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007, 192: 441-448. 10.1007\/s00213-007-0731-1.","journal-title":"Psychopharmacology (Berl)"},{"key":"560_CR30","first-page":"1","volume":"AiA","author":"RR Wu","year":"2008","unstructured":"Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH: Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2008, AiA: 1-7.","journal-title":"Am J Psychiatry"},{"key":"560_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","volume":"93","author":"T Baptista","year":"2007","unstructured":"Baptista T, Rangel N, Fernandez V, Carrizo E, El FY, Uzcategui E, Galeazzi T, Gutierrez MA, Servigna M, Davila A, Uzcategui M, Serrano A, Connell L, Beaulieu S, de Baptista EA: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007, 93: 99-108. 10.1016\/j.schres.2007.03.029.","journal-title":"Schizophr Res"},{"key":"560_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0924-977X(01)00072-4","volume":"11","author":"M Floris","year":"2001","unstructured":"Floris M, Lejeune J, Deberdt W: Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol. 2001, 11: 181-182. 10.1016\/S0924-977X(01)00072-4.","journal-title":"Eur Neuropsychopharmacol"},{"key":"560_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1176\/ajp.156.6.968a","volume":"156","author":"A Gordon","year":"1999","unstructured":"Gordon A, Price LH: Mood stabilization and weight loss with topiramate. Am J Psychiatry. 1999, 156: 968-969.","journal-title":"Am J Psychiatry"},{"key":"560_CR34","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4088\/JCP.v63n1116a","volume":"63","author":"E Levy","year":"2002","unstructured":"Levy E, Margolese HC, Chouinard G: Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002, 63: 1045-","journal-title":"J Clin Psychiatry"},{"key":"560_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1345\/aph.10414","volume":"35","author":"KH Littrell","year":"2001","unstructured":"Littrell KH, Petty RG, Hiligoss NM, Peabody CD, Johnson CG: Weight loss with topiramate. Ann Pharmacother. 2001, 35: 1141-1142. 10.1345\/aph.10414.","journal-title":"Ann Pharmacother"},{"key":"560_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","volume":"159","author":"JA Morrison","year":"2002","unstructured":"Morrison JA, Cottingham EM, Barton BA: Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002, 159: 655-657. 10.1176\/appi.ajp.159.4.655.","journal-title":"Am J Psychiatry"},{"key":"560_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.jcp.0000162806.46453.38","volume":"25","author":"MK Nickel","year":"2005","unstructured":"Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, Tritt K, Krawczyk J, Kettler C, Egger C, Rother WK, Loew TH: Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005, 25: 211-217. 10.1097\/01.jcp.0000162806.46453.38.","journal-title":"J Clin Psychopharmacol"},{"key":"560_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/hup.507","volume":"18","author":"CU Pae","year":"2003","unstructured":"Pae CU, Kim JJ, Lee KU, Lee CU, Bahk WM, Lee SJ, Lee C, Paik IH: Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. Hum Psychopharmacol. 2003, 18: 453-456. 10.1002\/hup.507.","journal-title":"Hum Psychopharmacol"},{"key":"560_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0006-3223(00)00872-6","volume":"48","author":"E Sacchetti","year":"2000","unstructured":"Sacchetti E, Guarneri L, Bravi D: H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry. 2000, 48: 167-168. 10.1016\/S0006-3223(00)00872-6.","journal-title":"Biol Psychiatry"},{"key":"560_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","volume":"162","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC: A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005, 162: 954-962. 10.1176\/appi.ajp.162.5.954.","journal-title":"Am J Psychiatry"},{"key":"560_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.2007.56-b","volume":"299","author":"RR Wu","year":"2008","unstructured":"Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008, 299: 185-193. 10.1001\/jama.2007.56-b.","journal-title":"JAMA"},{"key":"560_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4088\/JCP.v62n0204","volume":"62","author":"BJ Kinon","year":"2001","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001, 62: 92-100.","journal-title":"J Clin Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-9-12\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T17:29:01Z","timestamp":1684949341000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-9-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,28]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-9-12","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,28]]},"article-number":"12"}}